Insulin Receptor

Other Protein Tyrosine Kinase Related Inhibitors

VEGFR EGFR c-Met PDGFR CSF-1R IGF-1R c-Kit ALK Tie-2 HER2

Cat.No.	Product Name	Information	Product Use Citations	Product Validations
S6922	S961	S961 is a biosynthetic insulin receptor antagonist that inhibits cellular proliferation and colony formation in breast tumour cells.	Front Immunol, 2025, 16:1620571 Hepatol Commun, 2025, 9(9)e0793 J Neuroendocrinol, 2024, e13446.
S1091	Linsitinib (OSI-906)	Linsitinib (OSI-906) is a selective inhibitor of IGF-1R with IC50 of 35 nM in cell-free assays. It is modestly potent to InsR with IC50 of 75 nM, and shows no activity towards Abl, ALK, BTK, EGFR, FGFR1/2, PKA etc. Phase 3.	Nat Commun, 2025, 16(1):2493 Cell Rep Med, 2025, 6(8):102297 Cell Rep Med, 2025, 6(8):102254

Cat.No.

Product Name

Information

Product Use Citations

Product Validations

S6922

S961

S961 is a biosynthetic insulin receptor antagonist that inhibits cellular proliferation and colony formation in breast tumour cells.

Front Immunol, 2025, 16:1620571

Hepatol Commun, 2025, 9(9)e0793

J Neuroendocrinol, 2024, e13446.

S1091

Linsitinib (OSI-906)

Linsitinib (OSI-906) is a selective inhibitor of IGF-1R with IC50 of 35 nM in cell-free assays. It is modestly potent to InsR with IC50 of 75 nM, and shows no activity towards Abl, ALK, BTK, EGFR, FGFR1/2, PKA etc. Phase 3.

Nat Commun, 2025, 16(1):2493

Cell Rep Med, 2025, 6(8):102297

Cell Rep Med, 2025, 6(8):102254

Verified customer review of Linsitinib (OSI-906)